The NeuroIMAGE study: a prospective phenotypic, cognitive, genetic and MRI study in children with attention-deficit/hyperactivity disorder. Design and descriptives
- 1.7k Downloads
Attention-deficit/hyperactivity disorder (ADHD) is a persistent neuropsychiatric disorder which is associated with impairments on a variety of cognitive measures and abnormalities in structural and functional brain measures. Genetic factors are thought to play an important role in the etiology of ADHD. The NeuroIMAGE study is a follow-up of the Dutch part of the International Multicenter ADHD Genetics (IMAGE) project. It is a multi-site prospective cohort study designed to investigate the course of ADHD, its genetic and environmental determinants, its cognitive and neurobiological underpinnings, and its consequences in adolescence and adulthood. From the original 365 ADHD families and 148 control (CON) IMAGE families, consisting of 506 participants with an ADHD diagnosis, 350 unaffected siblings, and 283 healthy controls, 79 % participated in the NeuroIMAGE follow-up study. Combined with newly recruited participants the NeuroIMAGE study comprehends an assessment of 1,069 children (751 from ADHD families; 318 from CON families) and 848 parents (582 from ADHD families; 266 from CON families). For most families, data for more than one child (82 %) and both parents (82 %) were available. Collected data include a diagnostic interview, behavioural questionnaires, cognitive measures, structural and functional neuroimaging, and genome-wide genetic information. The NeuroIMAGE dataset allows examining the course of ADHD over adolescence into young adulthood, identifying phenotypic, cognitive, and neural mechanisms associated with the persistence versus remission of ADHD, and studying their genetic and environmental underpinnings. The inclusion of siblings of ADHD probands and controls allows modelling of shared familial influences on the ADHD phenotype.
KeywordsAttention-deficit/hyperactivity disorder Cognition Imaging Genetics Development Familiality
The NeuroIMAGE project was supported by NIH Grant R01MH62873 (to Stephen V. Faraone), NWO Large Investment Grant 1750102007010 and ZonMW Grant 60-60600-97-193 (to Jan Buitelaar), and grants from Radboud University Nijmegen Medical Center, University Medical Center Groningen and Accare, and VU University Amsterdam. We acknowledge the department of Pediatrics of the VU University Medical Center for giving us the opportunity to use their mock scanner for preparation of our participants. We thank Paul Gaalman and IT staff of the VU University Amsterdam for technical MRI assistance, all PhD students for their contribution to the data acquisition and are grateful to all participating families.
Conflict of interest
Jan Buitelaar has been in the past 3 years a consultant to/member of advisory board of/speaker for Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Shering Plough, UCB, Shire, Novartis and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents and royalties. Jaap Oosterlaan has been on the advisory board of Shire and UCB Pharmaceuticals. He has received an unrestricted grant from Shire. Pieter Hoekstra has received honoraria for advice from Eli Lilly and Shire. In the past year, Stephen V. Faraone received consulting income and/or research support from Shire, Otsuka and Alcobra and research support from the National Institutes of Health (NIH). In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. SVF receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health and Oxford University Press: Schizophrenia: The Facts. The other authors have no potentially competing interests.
- 3.American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4 edn. doi: 10.1176/appi.books.9780890423349
- 9.Willcutt E, Sonuga-Barke E, Nigg J, Sergeant J (2008) Recent developments in neuropsychological models of childhood psychiatric disorders. In: Banaschewski T, Rohde LA (eds) Biological child psychiatry. Recent trends and developments, vol 24. Karger Publishers, Basel, pp 195–226. doi: 10.1016/j.chc.2007.11.008
- 28.Lasky-Su J, Neale BM, Franke B et al (2008) Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B Neuropsychiatr Genet 147B:1345–1354. doi: 10.1002/ajmg.b.30867 CrossRefPubMedGoogle Scholar
- 37.Rommelse NNJ, Geurts HM, Franke B et al (2011) A review on cognitive and brain endophenotypes that may be common in autism spectrum disorder and attention-deficit/hyperactivity disorder and facilitate the search for pleiotropic genes. Neurosci Biobehav Rev 35:1363–1396. doi: 10.1016/j.neubiorev.2011.02.015 CrossRefPubMedGoogle Scholar
- 43.van Lieshout M, Luman M, Twisk JWR et al. Persistence rates and symptom change in attention-deficit/hyperactivity disorder (submitted)Google Scholar
- 44.Conners CK, Erhardt D, Sparrow E (1999) Conners’ adult ADHD rating scales: technical manual. Multi-Health Systems, New YorkGoogle Scholar
- 47.Saunders JB, Aasland OG, Babor TF et al (1993) Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 88:791–804. doi: 10.1111/j.1360-0443.1993.tb02093.x CrossRefPubMedGoogle Scholar
- 52.Lesieur HR, Blume SB (1987) The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers. Am J Psychiatry 144(9):1184–1188Google Scholar
- 54.Shaffer D, Fisher P, Lucas CP et al (2000) NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 39:28–38. doi: 10.1097/00004583-200001000-00014 CrossRefPubMedGoogle Scholar
- 55.Johnston L, O’Malley PM, Bachman JG (1998) National survey results on drug use from the Monitoring the Future Study, 1975–1997Google Scholar
- 57.Kaufman J, Birmaher B, Brent D et al (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988. doi: 10.1097/00004583-199707000-00021 CrossRefPubMedGoogle Scholar
- 66.Loeber R, Wung P, Keenan K, Giroux B, Stouthamer-Loeber M, Van Kammen WB, Maugham B (1993) Developmental pathways in disruptive child behavior. Dev Psychopathol 5(1–2):103–133Google Scholar
- 76.Wechsler D (2000) WAIS-III Nederlandstalige bewerking. Technische handleiding. The Psychological Corporation, LondonGoogle Scholar
- 77.Wechsler D (2002) WISC-III Handleiding. The Psychological Corporation, LondonGoogle Scholar
- 81.De Sonneville L (1999) Amsterdam neuropsychological tasks: a computer-aided assessment program. Computers in psychologyGoogle Scholar
- 84.Brus BT, Voeten M (1973) Een-Minuut-Test. Vorm A en B. Harcourt Test. Lisse, The NetherlandsGoogle Scholar